EMEA-002822-PIP01-20
Key facts
| Active substance |
2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glial fibrillary acidic protein pre-mRNA (ION373)
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0539/2021
|
| PIP number |
EMEA-002822-PIP01-20
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Alexander disease
|
| Route(s) of administration |
Intrathecal use
|
| Contact for public enquiries |
Ionis Pharmaceuticals
Email: globalregulatoryaffairs@ionisph.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|